What is the purpose of this trial?
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) as a corticosteroid (CS)-sparing agent in subjects with CS-dependent Myasthenia Gravis (MG).
Ages: 18 - 85 years
Grifols Worldwide Operations (formerly Grifols Therapeutics)
Start Date: 10/08/2015
End Date: 01/31/2017
Last Updated: 02/22/2018
Study HIC#: 1509016449